Stockscreener 앱 받기
0.4999
15.13%
0.0657
시간 외 거래:
.48
-0.0199
-3.98%
Actuate Therapeutics Inc 주식(ACTU)의 최신 뉴스
AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer - Zacks Investment Research
Actuate Therapeutics to sell 50 million shares at assumed $0.819 price - scanx.trade
Actuate Therapeutics Registers 50 Million Shares for Public Offering at $0.819 Each - Kalkine Media
At an assumed $0.819 a share, Actuate Therapeutics (Nasdaq: ACTU) proposes a stock offering. - Stock Titan
Gyre Therapeutics, Inc.Common Stock (Nasdaq:GYRE) Stock Quote - The Chronicle-Journal
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
Actuate Therapeutics Reports Synergistic Preclinical Activity of Elraglusib with RAS-Targeted Agents in Pancreatic Cancer Models - Quiver Quantitative
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to Buy - Yahoo Finance
12 Health Care Stocks Moving In Thursday's Intraday Session - Sahm
Actuate (ACTU) Results Check: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Closing Reaction: The Stock Gains 16.04% for the Current SessionInvestor Earnings Call - vinanet.vn
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move: Shares Move 0.95% Up at the CloseRevenue Estimate Trend - vinanet.vn
Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move - dars.gov.et
Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move - careplusvn.com
Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move: Shares Move 0.95% Up at the CloseEarnings Recovery Stocks - dars.gov.et
Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move - dars.gov.et
Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move: Shares Move 0.95% Up at the CloseSurprise Factor Analysis - dars.gov.et
Actuate (ACTU) Results Check: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Closing Reaction: The Stock Gains 16.04% for the Current SessionEarnings Revision Downgrade - https://www.dars.gov.et/
Actuate Therapeutics (ACTU) Holds $1.00 After 1.31% Gain, Pinned Between Key Support and ResistanceBullish Percent Index - vinanet.vn
Actuate Therapeutics stock gets FDA clearance for elraglusib trial By Investing.com - Investing.com Canada
Actuate Therapeutics (ACTU) Holds $1.00 After 1.31% Gain, Pinned Between Key Support and ResistanceInverse ETF Flow - dars.gov.et
Actuate Therapeutics (ACTU) Gains 3.58% to $1.01, Approaches Key Resistance at $1.06Bullish Pattern Stocks - vinanet.vn
Actuate Therapeutics Inc (ACTU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Actuate Therapeutics (ACTU) Pushes 3.58% Higher, Tests $1.06 Resistance ZoneButterfly Setup - dars.gov.et
Actuate Therapeutics (ACTU) Pushes 3.58% Higher, Tests $1.06 Resistance ZoneQuote Data - vinanet.vn
Actuate Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Actuate Therapeutics (ACTU) CEO RSUs Vest, 120,521 Shares Withheld for Taxes - Stock Titan
Actuate Therapeutics (NASDAQ: ACTU) narrows loss but warns on cash runway - Stock Titan
Actuate Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Actuate Therapeutics (ACTU) Holds Near $0.97 as Support Test LoomsButterfly Setup - vinanet.vn
ACTU Q1 2026 Earnings: Wider-than-Expected Loss Reflects Ongoing R&D InvestmentEarnings Outlook Update - Vinanet
ETFs Investing in Actuate Therapeutics, Inc. Stocks - TradingView
Actuate Therapeutics Inc (ACTU) Stock News Today - TradingKey
Actuate Therapeutics (ACTU) Surges 8.85% to $1.23 as Buyers Defend Key SupportOvernight Profile - vinanet.vn
CNSY Stock Price and Chart — NASDAQ:CNSY - tradingview.com
Actuate Therapeutics, Inc. Revenue Breakdown – NASDAQ:ACTU - TradingView
Rodman & Renshaw Initiates Actuate Therapeutics(ACTU.US) With Buy Rating, Announces Target Price $6 - Moomoo
Actuate Therapeutics stock initiated with buy rating at Rodman & Renshaw - Investing.com Nigeria
Actuate Therapeutics Inc (ACTU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Actuate Therapeutics Inc (ACTU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Actuate Therapeutics Inc (ACTU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Actuate Therapeutics Inc (ACTU) Valuation: PE, PB & Fair Value Analysis - TradingKey
Actuate Therapeutics Inc (ACTU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Actuate Therapeutics Inc (ACTU) Cash Flow - TradingKey
Actuate Therapeutics Inc (ACTU) Balance Sheet - TradingKey
Actuate Therapeutics Inc (ACTU) Income Statement - TradingKey
Actuate Therapeutics Inc (ACTU) Institutional Confidence - TradingKey
Actuate Therapeutics Inc (ACTU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ACTU|Actuate Therapeutics Inc|Price:1.140|Chg%:-0.040 - TradingKey
1.35%
자본화:
|
볼륨(24시간):